Rezultati - Sarah Badaoui
- Showing 1 - 3 results of 3
-
1
The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy od Sarah Badaoui, Adel Shahnam, Ross A. McKinnon, Ahmad Y. Abuhelwa, Michael J. Sorich, Ashley M. Hopkins
Izdano 2022Artigo -
2
Efficacy of Atezolizumab in Patients With Advanced NSCLC Receiving Concomitant Antibiotic or Proton Pump Inhibitor Treatment: Pooled Analysis of Five Randomized Control Trials od Ashley M. Hopkins, Sarah Badaoui, Ganessan Kichenadasse, Christos S. Karapetis, Ross A. McKinnon, Andrew Rowland, Michael J. Sorich
Izdano 2022Artigo -
3
Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150 od Ashley M. Hopkins, Ganessan Kichenadasse, Ross A. McKinnon, Ahmad Y. Abuhelwa, Jessica M. Logan, Sarah Badaoui, Christos S. Karapetis, Andrew Rowland, Michael J. Sorich
Izdano 2021Artigo
Iskalna orodja:
Sorodne teme
Atezolizumab
Cancer
Immunotherapy
Internal medicine
Medicine
Oncology
Lung cancer
Nivolumab
Antibiotics
Bevacizumab
Biology
Carboplatin
Chemoimmunotherapy
Chemotherapy
Cisplatin
Concomitant
Confidence interval
Gastroenterology
Hazard ratio
Microbiology
Paclitaxel
Pembrolizumab
Performance status
Post-hoc analysis
Proton-pump inhibitor
Randomized controlled trial